Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these studies are limited to particular cancer types and subsets of patients, due to difference in mutation load seen in different cancer types, and immune-related adverse effects of therapy may occur [93][94][95][96].”
From Cancer-on-chip models for metastasis: importance of the tumor microenvironment (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these markers have clinical utility in specific contexts, their predictive accuracy varies considerably across tumor histologies and patient populations.”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While high TMB and immune checkpoint molecule expression, including PD-L1, have been used as predictive biomarkers across different cancer types, they have limited clinical utility when considered in isolation88,101.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [88]
Experimental — accuracy not yet measuredIn the citing paper
“Although high TMB led to FDA approval, it should be noted that certain tumor types with moderate TMB carry relatively high response rates to ICT, such as clear cell RCC (128, 129).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [128]
In the citing paper
“Melanoma, lung, and bladder cancer, tumors commonly associated with an increased number of mutations due to environmental DNA damage, exhibit a stronger response to ICB (Yarchoan et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Yarchoan et al., 2017
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Cited by
Items 701–800 of 1,006
Wong, C. N., Fessas, P., Dominy, K., Mauri, F. A., Kaneko, T., Parcq, P. D., Khorashad, J. S., Toniutto, P., Goldin, R. D., Avellini, C., et al. (2020) · Liver International · doi:10.1111/liv.14706 · Cited by 49
Molecular Profiling–Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges
Zhang, Q., Fu, Q., Bai, X., & Liang, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.532403 · Cited by 51
“Molecular alternations, such as BRAF mutations (6), NTRK family fusion (7), and microsatellite instability (8), have been linked to responses to matched agents in a variety of tumor types.”
BackgroundKlein, O., Senko, C., Carlino, M. S., Markman, B., Jackett, L. A., Gao, B., Lum, C., Kee, D., Behren, A., Palmer, J., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1908771 · Cited by 51
“TMB has been associated with treatment response to checkpoint inhibition across a range of malignancies.(21) The majority of tumors in our cohort had a low TMB in keeping with previous reports demonstrating that ACC is one of the malignancies with the lowest TMB.”
ResultAbscopal Effects of Local Radiotherapy Are Dependent on Tumor Immunogenicity
Lai, J., Zhu, Y., Liu, Y., Zhou, L., Hu, L., Chen, L., & Zhang, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.690188 · Cited by 54
Mastracci, L., Grillo, F., Parente, P., Gullo, I., Campora, M., Angerilli, V., Rossi, C., Sacramento, M. L., Pennelli, G., Vanoli, A., et al. (2022) · Pathologica · doi:10.32074/1591-951x-803 · Cited by 51
Dempke, W. C. M., Fenchel, K., & Dale, S. P. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.04.18 · Cited by 46
“com (TMB) or gene signatures may be an ideal strategy guiding treatment decisions for checkpoint inhibitors (15,16).”
BackgroundImmune checkpoint inhibitors in cervical cancer: Current status and research progress
Xie, Y., Kong, W., Zhao, X., Zhang, H., Luo, D., & Chen, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.984896 · Cited by 50
“As many studies have shown correlations between TMB and response to ICI therapies in multiple tumors (36, 37), TMB has been used as a biomarker to predict the response to immune checkpoint inhibitor treatment (38).”
MethodNecchi, A., Spiess, P. E., de Pádua, T. C., Li, R., Grivas, P. D., Huang, R. S. P., Lin, D. I., Danziger, N. A., Ross, J. S., Jacob, J. M., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.48002 · Cited by 48
NCOA3 impairs the efficacy of anti-PD-L1 therapy via HSP90α/EZH2/CXCL9 axis in colon cancer
Liu, J., Su, Y., Zhang, C., Dong, H., Yu, R., Yang, X., Tian, Y., Feng, Y., Zhang, J., Shi, M., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114579 · Cited by 47
The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
Meti, N., Esfahani, K., & Johnson, N. A. (2018) · Cancers · doi:10.3390/cancers10060204 · Cited by 51
“In solid tumors, PD-1 inhibitors eliciting a CD8+ mediated cytotoxicity and neoantigen exposure from increased mutation burden is a predictive marker of response [103,104].”
BackgroundLi, J., Ybarra, R., Mak, J., Hérault, A., de Almeida, P. E., Arrazate, A., Ziai, J. M., Tótpál, K., Junttila, M. R., Walsh, K. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1139 · Cited by 48
“coding sequence in tumor DNA) and the objective response rate to anti–PD-1 therapy within multiple indications (11).”
BackgroundBioinformatic methods for cancer neoantigen prediction
Boegel, S., Castle, J. C., Kodysh, J., O'Donnell, T., & Rubinsteyn, A. (2019) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2019.06.016 · Cited by 44
Carroll, M. R., Ramalingam, P., Salvo, G., Fujimoto, J., Soto, L. M. S., Phoolcharoen, N., Hillman, R. T., Cardnell, R. J., Byers, L. A., & Frumovitz, M. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001649 · Cited by 54
Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review
Haibe, Y., Husseini, Z. E., Sayed, R. E., & Shamseddine, A. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176176 · Cited by 48
“Finally, there are tumor associated antigens, usually overexpressed in tumor cells, such as Her-2 protein, weakly expressed in normal tissues [35,40].”
BackgroundChen, J., Hu, X., Li, Q., Dai, W., Cheng, X., Huang, W. M., Yu, W., Chen, M., Guo, Y., & Yuan, G. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6063 · Cited by 46
RetractedCholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches
Khosla, D., Misra, S., Chu, P. L., Guan, P., Nada, R., Gupta, R., Kaewnarin, K., Ko, T. K., Heng, H. L., Srinivasalu, V. K., et al. (2024) · Cancers · doi:10.3390/cancers16040801 · Cited by 44
“An elevated TMB was found to correlate with a better response rate to the immune checkpoint blockade treatment; however, this remains to be determined for AA-CCA [42].”
BackgroundCui, Y., Miao, Y., Cao, L., Guo, L., Cui, Y., Yan, C., Zeng, Z., Xu, M., & Han, T. (2023) · Nature Communications · doi:10.1038/s41467-023-41101-3 · Cited by 45
“However, the therapeutic bene fi t of ICB is limited to a subset of patients in each cancer type despite the use of predictive biomarkers such as PD-L1 expression, tumor mutation burden, and mismatch repair de fi ciency 6 – 8 .”
Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility
Leonard‐Murali, S., Bhaskarla, C., Yadav, G. S., Maurya, S. K., Galiveti, C. R., Tobin, J. A., Kann, R. J., Ashwat, E., Murphy, P. S., Chakka, A. B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46906-4 · Cited by 50
Liquid biopsies for hepatocellular carcinoma
Su, Y., Kim, A. K., & Jain, S. (2018) · Translational research · doi:10.1016/j.trsl.2018.07.001 · Cited by 47
“Tumor mutational burden (TMB; total number of mutations per coding area of tumor genome), measured in tumor tissue by whole exome sequencing, is a biomarker for predicting response to immunotherapy.(151,152) Recent studies have shown that TMB can be accurately measured in smaller gene panels limited to several hundred…”
Davis, D. A., Shrestha, P., Aisabor, A. I., Stream, A., Galli, V., Pise-Masison, C. A., Tagawa, T., Ziegelbauer, J. M., Franchini, G., & Yarchoan, R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1546544 · Cited by 46
“Checkpoint inhibition therapy requires epitopes in the target cells that can be recognized by T-cells and have been shown to be especially effective against tumors with multiple mutations.(72) This therapy can also be useful in virus-associated tumors as the viruses provide foreign”
BackgroundNew therapies and insights into the changing landscape of colorectal cancer
Kopetz, S. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0100-z · Cited by 45
Takenaka, M., Köbel, M., Garsed, D. W., Fereday, S., Pandey, A., Etemadmoghadam, D., Hendley, J., Kawabata, A., Noguchi, D., Yanaihara, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3691 · Cited by 53
Bewersdorf, J. P., Shallis, R. M., & Zeidan, A. M. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100709 · Cited by 51
Pradhan, M., Chocry, M., Gibbons, D. L., Sepesi, B., & Cascone, T. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-573 · Cited by 50
“Tumor mutation burden (TMB) refers to the total number of missense somatic mutations within tumor genome that gives rise to tumor-specific neoantigens which in turn can activate the host T cell response against tumor (49).”
BackgroundBiomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors
Zeng, Z., Yang, B., & Liao, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650481 · Cited by 48
“Recently, TMB has evolved as an emerging biomarker in immunotherapy, especially in terms of drug-response and prognosis prediction (51, 52).”
BackgroundAssociation between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors
Ahmed, M., von Itzstein, M. S., Sheffield, T. Y., Khan, S., Fattah, F. J., Park, J. Y., Popat, V., Saltarski, J. M., Gloria-McCutchen, Y., Hsiehchen, D., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002349 · Cited by 46
Bongiorno, R., Colombo, M. P., & Lecis, D. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02192-2 · Cited by 46
“It is possible to speculate that there could be a correlation between TMB and/or mismatch repair-deficiency, and efficacy of NMD inhibition in cancer, as already observed for anti–PD-1 or anti–PDL1 therapy [103].”
BackgroundRationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Tai, D. W.-M., Choo, S. P., & Chew, V. (2019) · Cancers · doi:10.3390/cancers11121926 · Cited by 46
“In this study, TMB level is considered moderate for HCC, consistent with a modest response rate to ICB in HCC [63].”
BackgroundPrognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy
Cai, H., Zhang, Y., Zhang, H., Cui, C., Li, C., & Lu, S. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.25859 · Cited by 53
“emerged as a novel potential biomarker in immune checkpoint inhibitor (ICI) therapy and is correlated with an objective response rate of ICIs in many tumor types.(9) For example, studies conducted by Carbone et al(10) and Hamid et al(11) suggested that TMB was associated with the efficiency of ICIs in patients with ad…”
ResultHeydt, C., Rehker, J., Pappesch, R., Buhl, T., Ball, M., Siebolts, U., Haak, A., Lohneis, P., Büttner, R., Hillmer, A. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68394-4 · Cited by 45
Spectrum of Nonkeratinocyte Skin Cancer Risk Among Solid Organ Transplant Recipients in the US
Sargen, M. R., Cahoon, E. K., Yu, K. J., Madeleine, M. M., Zeng, Y., Rees, J. R., Lynch, C. F., & Engels, E. A. (2022) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.0036 · Cited by 45
Genomic characterization of lymphomas in patients with inborn errors of immunity
Ye, X., Maglione, P. J., Wehr, C., Li, X., Wang, Y., Abolhassani, H., Deripapa, E. V., Liu, D., Borte, S., Du, L., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006654 · Cited by 45
Brandi, N., & Renzulli, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108598 · Cited by 45
Su, F., Zhang, Y., Zhang, D., Zhang, Y., Pang, C., Huang, Y., Wang, M., Cui, L., He, L., Zhang, J., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.06.005 · Cited by 45
Significant function and research progress of biomarkers in gastric cancer (Review)
Ye, D., Xu, G., Ma, W., Li, Y., Luo, W., Xiao, Y., Liu, Y., & Zhang, Z. (2019) · Oncology Letters · doi:10.3892/ol.2019.11078 · Cited by 54
“However, there are some difficulties in assessing TMB in clinical practice, including a long detection period, poor platform accessibility, high costs and inconsistent standards.”
BackgroundInfluentialLabadie, B. W., Liu, P., Bao, R., Crist, M., Fernandes, R., Ferreira, L., Graupner, S., Poklepovic, A. S., Durán, I., Vareki, S. M., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-02144-7 · Cited by 45
Balancing Cancer Immunotherapy Efficacy and Toxicity
Johnson, D. B., Jakubovic, B. D., Sibaud, V., & Sise, M. E. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.06.028 · Cited by 49
“Response rates for antiePD-1/PD-L1 vary widely from 80% to 90% (for Hodgkin lymphoma) to 45% to 60% (for skin cancers and microsattelite unstable cancers) to 15% to 30% (for many other solid tumors including cancers of the lung, kidney, bladder, and head and neck).(2) In contrast, antieCTLA-4 has a lower degree of act…”
Sarcoma and the 100,000 Genomes Project: our experience and changes to practice
Prendergast, S., Strobl, A., Cross, W. C. H., Pillay, N., Strauss, S. J., Ye, H., Lindsay, D., Tirabosco, R., Chalker, J., Mahamdallie, S., et al. (2020) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.174 · Cited by 44
“Tumour mutational burden can be used as a biomarker to stratify patients for treatment with checkpoint inhibitors [20].”
BackgroundHu, H., She, L., Liao, M., Shi, Y., Yao, L., Ding, D., Zhu, Y., Zeng, S., Carbone, D. P., & Huang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01649 · Cited by 44
Li, S., Zhang, C., Pang, G., & Wang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.603157 · Cited by 46
“TMB is the total number of non-synonymous somatic mutations per megabase in the coding region of the cancer genome (14).”
BackgroundEffect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
Chen, C., Liu, Y., & Cui, B. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1840254 · Cited by 45
“the development of resistance toward PD-1/PD-L1 therapy.(125,128,141,142)”
Bian, C., Wang, Y., Lu, Z., An, Y., Wang, H., Kong, L., Du, Y., & Tian, J. (2021) · Cancers · doi:10.3390/cancers13071659 · Cited by 39
“Moreover, tumor gene mutation status is also of vital importance for the prediction of drug efficacy [9], disease-free survival [10], and immunotherapy response [11,12].”
BackgroundGuo, X., Liang, X., Wang, Y., Cheng, A., Zhang, H., Qin, C., & Wang, Z. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.642608 · Cited by 49
Jiang, C., Li, X., Pan, F., Zhang, L., Yu, H., Zhang, J., Zou, J., Zhong, T., Zhang, D., Yang, Y., et al. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202211698 · Cited by 42
State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation
Pathak, P., Chan, G. H. J., Deming, D. A., & Chee, C. E. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438466 · Cited by 49
Lurain, K. A., Ramaswami, R., Krug, L. T., Whitby, D., Ziegelbauer, J. M., Wang, H., & Yarchoan, R. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00022-23 · Cited by 44
“Checkpoint inhibitors, such as those that target programmed death-1 (PD-1), have revolutionized treatment of a number of cancers, especially those with a high mutational burden (322, 323).”
The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions
Rina, A., Maffeo, D., Minnai, F., Esposito, M., Palmieri, M., Serio, V. B., Rosati, D., Mari, F., Frullanti, E., & Colombo, F. (2024) · Cancers · doi:10.3390/cancers16162882 · Cited by 57
“TMB, quantified by the number of mutations per megabase of DNA, has gained prominence as a biomarker, with elevated TMB levels indicating a higher likelihood of producing immunogenic neo-antigens capable of eliciting a T-cell response [259].”
BackgroundChaudhary, R., Quagliata, L., Jermann, P. M., Alborelli, I., Cyanam, D., Mittal, V., Tom, W., Au-Young, J. K., Sadis, S. E., & Hyland, F. C. L. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.01 · Cited by 46
“More recently, an association between the median TMB and objective response rate across multiple cancer types was established (20).”
BackgroundMolecular biology of oral cavity squamous cell carcinoma
Hsu, P. J., Yan, K. K.-L., Shi, H., Izumchenko, E., & Agrawal, N. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104552 · Cited by 47
Expression of Tryptophan 2,3-Dioxygenase in Metastatic Uveal Melanoma
Terai, M., Londin, E. R., Rochani, A., Link, E., Lam, B., Kaushal, G., Bhushan, A., Orloff, M. M., & Sato, T. (2020) · Cancers · doi:10.3390/cancers12020405 · Cited by 46
“A variety of mechanisms may account for such resistance to ICIs, including low tumor mutational burden and low tumor neoantigen expression [22].”
BackgroundMatsuki, T., Okamoto, I., Fushimi, C., Sawabe, M., Kawakita, D., Sato, H., Tsukahara, K., Kondo, T., Okada, T., Tada, Y., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3124 · Cited by 42
Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer
Lurain, K. A., Ramaswami, R., Yarchoan, R., & Uldrick, T. S. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00525-y · Cited by 43
Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer
Zhou, H., Chen, L., Lei, Y., Li, T., Li, H., & Cheng, X. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100660 · Cited by 48
Andersson, D., Kristiansson, H., Kubista, M., & Ståhlberg, A. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1889371 · Cited by 43
“For example, tumor mutational burden is used as a predictive biomarker in immunotherapy where high tumor mutational burden is associated with increased response rate [164], such”
BackgroundShi, Y., Li, D., He, C., & Chen, X. (2021) · Macromolecular Bioscience · doi:10.1002/mabi.202100049 · Cited by 42
Chen, X., Fang, L., Zhu, Y., Bao, Z., Wang, Q., Liu, R., Sun, W., Du, H., Lin, J., Yu, B., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02943-2 · Cited by 42
“Furthermore, a meta-analysis spanning 27 cancer types confirmed the positive association [16].”
BackgroundCurrent Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma
Yavuz, B. G., Hasanov, E., Lee, S. S., Mohamed, Y. I., Curran, M. A., Koay, E. J., Cristini, V., & Kaseb, A. O. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s322289 · Cited by 43
TNFSF13 Is a Novel Onco-Inflammatory Marker and Correlates With Immune Infiltration in Gliomas
Chen, R., Wang, X., Dai, Z., Wang, Z., Wu, W., Hu, Z., Zhang, X., Liu, Z., Zhang, H., & Cheng, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.713757 · Cited by 46
“Mismatch repair, MSI, TMB have all been proposed to be responsible for tumor growth and could efficiently predict immunotherapy responses (61).”
BackgroundInfluentialde Bitter, T. J. J., de Reuver, P. R., Lohman, E. A. J. D. S., Kroeze, L. I., Vink-Börger, M. E., van Vliet, S., Simmer, F., von Rhein, D. T., Jansen, E. A. M., Verheij, J., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00327-y · Cited by 45
Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
Yiong, C. S., Lin, T. P., Lim, V., Toh, T. B., & Yang, V. S. (2023) · Biomarker Research · doi:10.1186/s40364-023-00513-5 · Cited by 46
“As predicted, improved survival after ICI treatment was indeed observed in patients with high TMB in multiple cancer types [96, 97].”
BackgroundGiannakopoulou, E., Lehander, M., Culleton, S. V., Yang, W., Li, Y., Kärpänen, T., Yoshizato, T., Rustad, E. H., Nielsen, M. M., Bollineni, R. C., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00642-8 · Cited by 45
Wang, C., Liu, T.-C., Lai, P.-J., Muzakky, H., Wang, Y., Yu, M.-H., Wu, C.-H., & Chao, T. (2024) · Medical Image Analysis · doi:10.1016/j.media.2024.103372 · Cited by 46
de Jager, V. D., Giacomini, P., Fairley, J. A., Toledo, R. A., Patton, S. J., Joosse, S. A., Koch, C., Deans, Z. C., Agelaki, S., Andersen, C. L., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105636 · Cited by 44
A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas
Orth, M. F., Bücklein, V., Kampmann, E., Subklewe, M. S., Noeßner, E., Cidre‐Aranaz, F., Romero‐Pérez, L., Wehweck, F. S., Lindner, L. H., Issels, R. D., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02552-5 · Cited by 44
“This is in line with prior studies in other cancers correlating mutational burden, which is much higher in UPS compared to leiomyosarcoma and liposarcoma [31], with enhanced neoantigen presentation [32, 33].”
ResultIs There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
Jimbu, L., Mesaros, O., Popescu, C., Neaga, A., Berceanu, I., Dima, D. M., Găman, M., & Zdrenghea, M. (2021) · Pharmaceuticals · doi:10.3390/ph14040288 · Cited by 45
“Moreover, as expected, a high expression of PD-L1 on tumor cells is associated with better response to checkpoint inhibitors [59].”
BackgroundHyperthermia and Tumor Immunity
Adnan, A., Muñoz, N. M., Prakash, P., Habibollahi, P., Cressman, E. N. K., & Sheth, R. A. (2021) · Cancers · doi:10.3390/cancers13112507 · Cited by 42
“Unfortunately, the objective response rates to checkpoint inhibitor therapy remain below 50% across all malignancies [17].”
BackgroundPrognostic and immunological role of CD36: A pan-cancer analysis
Chen, Y., Liao, W., Huang, S., Yu, Y., Wen, J., Chen, J., Lin, D., Wu, X., Jiang, N., & Li, X. (2021) · Journal of Cancer · doi:10.7150/jca.50502 · Cited by 43
“TMB is used to reflect the number of mutations contained in tumor cells and is a quantifiable biomarker [25, 26].”
MethodPalicelli, A., Croci, S., Bisagni, A., Zanetti, E., de Biase, D., Melli, B., Sanguedolce, F., Ragazzi, M., Zanelli, M., Chaux, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212330 · Cited by 43
“Both HLA-ABC and PD-L1 are upregulated by IFN-γ via STAT1 phosphorylation [168].”
BackgroundTP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer
Zhang, Z., Hao, R., Guo, Q., Zhang, S., & Wang, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.759154 · Cited by 49
“We evaluated the potential role of the TP53 mutation in the immune therapy response, including the tumor mutation burden (TMB), microsatellite instability (MSI), and tumor immune dysfunction and exclusion (TIDE).”
BackgroundInfluentialMedici, B., Riccò, B., Caffari, E., Zaniboni, S., Salati, M., Spallanzani, A., Garajová, I., Benatti, S., Chiavelli, C., Dominici, M., et al. (2023) · Cancers · doi:10.3390/cancers15133509 · Cited by 50
Yu, I., Dakwar, A., & Takabe, K. (2023) · Cells · doi:10.3390/cells12020258 · Cited by 40
“Additionally, pMMR CRC has a lower mutational burden and fewer antigens that can be detected by cytotoxic T cells, which are associated with a poor response to ICIs [43,46].”
BackgroundZhang, H., Wang, Z., Dai, Z., Wu, W., Cao, H., Li, S., Zhang, N., & Cheng, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694490 · Cited by 52
“(D) TMB expression differences in high and low ICP score.”
BackgroundInfluentialFukuhara, M., Muto, S., Inomata, S., Yamaguchi, H., Mine, H., Takagi, H., Ozaki, Y., Watanabe, M., Inoue, T., Yamaura, T., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03067-3 · Cited by 42
Regulation of LncRNAs in Melanoma and Their Functional Roles in the Metastatic Process
Melixetian, M. B., Pelicci, P. G., & Lanfrancone, L. (2022) · Cells · doi:10.3390/cells11030577 · Cited by 46
Shao, W., Zhao, H., Zhang, S., Ding, Q., Guo, Y., Hou, K., Kan, Y., Deng, F., & Xu, Q. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1049183 · Cited by 43
“Several studies have demonstrated that tumor mutation burden (TMB) and microsatellite instability (MSI) stimulate lymphocyte antitumor responses and help the immune system recognize tumors (32, 33).”
BackgroundZhao, J., Sun, Z., Yu, Y., Yuan, Z., Lin, Y., Tan, Y., Duan, X., Yao, H., Wang, Y., & Liu, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006514 · Cited by 43
Lehmann, B. D., Abramson, V. G., Dees, E. C., Shah, P. D., Ballinger, T. J., Isaacs, C. J., Santa-Maria, C. A., An, H., Ericsson, P. I. G., Sanders, M. E., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.5424 · Cited by 48
Immunotherapy for Head and Neck Squamous Cell Carcinoma: Current Status and Perspectives
Daste, A., Larroquette, M., Gibson, N., Lasserre, M., & Domblides, C. (2023) · Immunotherapy · doi:10.2217/imt-2023-0174 · Cited by 43
An immunogenetic basis for lung cancer risk
Krishna, C., Tervi, A. M., Saffern, M., Wilson, E. A., Yoo, S., Mars, N., Roudko, V., Cho, B. A., Jones, S. E., Vaninov, N., et al. (2024) · Science · doi:10.1126/science.adi3808 · Cited by 48
Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges
Rizzo, A., Brunetti, O., & Brandi, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011091 · Cited by 45
“However, Yarchoan and colleagues suggested that HCC had a low number of somatic mutations encoded per megabase [68].”
BackgroundEndogenous thymic regeneration: restoring T cell production following injury
Granadier, D., Acenas, D. D., II, & Dudakov, J. A. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-024-01119-0 · Cited by 44
“…well-recognized correlation between the mutational burden of a tumour and response to immunotherapy such as immune checkpoint blockade; however, this correlation depends on the TCR repertoire being sufficiently broad that a specific T cell response can be mounted to tumour neoantigens 214,217–219 .”
Oing, C., Skowron, M. A., Bokemeyer, C., & Nettersheim, D. (2019) · Andrology · doi:10.1111/andr.12611 · Cited by 40
“Importantly, GCTs usually harbor an overall low mutational burden and no exceptional driver mutation for GCT development has been identified (Oosterhuis & Looijenga, 2005; Yarchoan et al., 2017).”
BackgroundPrecision oncology of lung cancer: genetic and genomic differences in Chinese population
Shen, H., Zhu, M., & Wang, C. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0086-1 · Cited by 43
Saigí, M., Alburquerque-Béjar, J. J., & Sánchez‐Céspedes, M. (2019) · Oncogene · doi:10.1038/s41388-019-0855-x · Cited by 41
Zhang, S., Bai, X., & Shan, F. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106247 · Cited by 43
A novel approach combined transfer learning and deep learning to predict TMB from histology image
Wang, L., Jiao, Y., Qiao, Y., Zeng, N., & Yu, R. (2020) · Pattern Recognition Letters · doi:10.1016/j.patrec.2020.04.008 · Cited by 48
Flickinger, J. C., Singh, J., Carlson, R. D., Leong, E., Baybutt, T. R., Barton, J. R., Caparosa, E. M., Pattison, A. M., Rappaport, J. A., Roh, J. W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001046 · Cited by 40
“7 Indeed, examination of neoepitopes presented on the surface of five colorectal cancer specimens revealed a total of three neoepitopes.”
Takahara, T., Murase, Y., & Tsuzuki, T. (2020) · Pathology · doi:10.1016/j.pathol.2020.09.004 · Cited by 42
Zhao, Y., Zhang, M., Pu, H., Guo, S., Zhang, S., & Wang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.585961 · Cited by 48
Xiang, Y., Chen, L., Liu, C., Yi, X., Li, L., & Huang, Y. (2021) · Small · doi:10.1002/smll.202104591 · Cited by 40
Wnt activation promotes memory T cell polyfunctionality via epigenetic regulator PRMT1
Sung, B.-Y., Lin, Y.-H., Kong, Q., Shah, P. D., Bieler, J. G., Palmer, S., Weinhold, K. J., Chang, H.-R., Huang, H., Avery, R. K., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci140508 · Cited by 43
“Despite remarkable successes using checkpoint blockade antibodies to treat metastatic cancer (12, 14), only a portion of patients benefit from this type of treatment (15, 16); this is partially due to the fact that the molecular mechanisms governing T cell polyfunctionality are not fully understood.”
BackgroundBenoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39
“TMB has been proposed as a biomarker of the response to anti-PD-1 therapy [12].”
BackgroundTang, P. C., Chan, M. K., Chung, J. Y., Chan, A. S. W., Zhang, D., Li, C., Leung, K. T., Ng, C. S. H., Wu, Y., To, K., et al. (2023) · Advanced Science · doi:10.1002/advs.202302203 · Cited by 46
Tasaki, Y., Sugiyama, Y., Hamamoto, S., Naiki, T., Uemura, T., Yokota, K., Kawakita, D., Nakamura, M., Ogawa, R., Shimura, T., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6724 · Cited by 41
“29 Melanoma have the highest rate of TMB ≥ 10 mutation/Mb. 28 The urothelial carcinoma and gastrointestinal cancer treated anti-PD-1 monotherapy have lower TMB ≥ 10 mutation/M than melanoma, lung cancer, and head and neck cancer.”
BackgroundAdvances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide
Paulson, K. G., & Bhatia, S. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7049 · Cited by 40
Targeting T Cell Activation in Immuno-Oncology
Saibil, S. D., & Ohashi, P. S. (2020) · Current Oncology · doi:10.3747/co.27.5285 · Cited by 42
Yang, B., Bai, J., Shi, R., Shao, X., Yang, Y., Jin, Y., Che, X., Zhang, Y., Qu, X., Liu, Y., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106532 · Cited by 60
Alerting the immune system to DNA damage: micronuclei as mediators
MacDonald, K. M., Benguerfi, S., & Harding, S. M. (2020) · Essays in Biochemistry · doi:10.1042/ebc20200016 · Cited by 43
Peptides that immunoactivate the tumor microenvironment
Furukawa, N., & Popel, A. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188486 · Cited by 37
Comprehensive molecular profiling broadens treatment options for breast cancer patients
Kawaji, H., Kubo, M., Yamashita, N., Yamamoto, H., Kai, M., Kajihara, A., Yamada, M., Kurata, K., Kaneshiro, K., Harada, Y., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3619 · Cited by 43
Metadata
- Authors
- Yarchoan, M., Hopkins, A., & Jaffee, E. M.
- Affiliations
- Johns Hopkins University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-21
- Volume
- 377
- Issue
- 25
- Pages
- 2500-2501
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6549688
- OpenAlex
- W2779221466
- Cited by
- 3,230
- References
- 5
- Citations by year
- 2026: 181 · 2025: 274 · 2024: 410 · 2023: 460 · 2022: 525 · 2021: 558 · 2020: 408 · 2019: 255 · 2018: 153 · 2017: 1
- FWCI
- 98.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor mutational burden, anti-PD-1 therapy, PD-L1 blockade, immune checkpoint inhibitors, cancer immunotherapy response, predictive biomarkers, cancer types
- MeSH terms
- Antineoplastic Agents, DNA Mutational Analysis, Humans, Models, Genetic, Mutation, Neoplasms, Biomarkers, Tumor, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.